Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas

Next Previous
Trial Profile

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 19 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Venetoclax (Primary) ; Vincristine (Primary)
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 04 Jun 2024 According to Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology, study did not meet its primary endpoint in phase II, and so did not proceed to phase III.
  • 04 Jun 2024 Primary endpoint has not been met (PFS progression-free survival : phase III) , according to Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 04 Jun 2024 Results (n=119) reporting initial phase II data from the DEL cohort presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top